

August 20, 2025

To,
The Manager,
Dept. of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Dear Sir/Madam,

Subject : Receipt of major pre-clinical testing contract valued at ₹10.75 Crores for a novel molecule in collaboration with a leading organization – Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Scrip Code : 511509

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Company, has secured a major pre-clinical testing contract valued at ₹10.75 Crores for a novel molecule in collaboration with a leading organization.

The details as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as "Annexure A"

Please find attached herewith the copy of the press release in this regard.

Kindly take the above information on your record.

Thanking You,

For Vivo Bio Tech Limited

A V Kiran
Company Secretary

Encl. as above

Annexure –A

Details in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S.No.	Particulars	Description
1.	Name of the entity to which order(s)/contract(s) is awarded;	Vivo Bio Tech Limited (the Company)
2.	Whether order(s) / contract(s) is awarded to domestic/ international entity	Domestic entity
3.	Significant terms and conditions of order(s)/contract(s) awarded, in brief;	<p>This contract entrusts Vivo Bio Tech Limited with the responsibility of conducting the entire spectrum of pre-clinical safety and regulatory studies. The scope of work includes:</p> <ol style="list-style-type: none"> 1. Toxicity studies across multiple endpoints 2. Mutagenicity evaluations to assess genetic safety 3. Ecotoxicology studies for environmental risk assessment 4. Comprehensive analytical services
5.	Time period, if any, associated with the order(s)/contract(s);	Upto 2 years
6.	Broad commercial consideration or size of the order(s)/contract(s);	Contract valued at ₹10.75 Crores
7.	Whether the promoter/ promoter group/group companies have any interest in that entity to whom the order(s)/contract(s) is awarded? If Yes, nature of interest and details thereof;	Not Applicable
8.	Whether the same would fall within related party transactions? If yes, whether the same is done at “arm’s length”.	Not Applicable

Press Release

Vivo Bio Tech Limited Secures Landmark Pre-Clinical Testing Contract Valued at ₹10.75 Crores

Vivo Bio Tech Limited announces a significant milestone in its growth journey. The company has been awarded a pre-clinical testing contract valued at ₹10.75 Crores for a novel molecule, in collaboration with a leading Indian Pharma and Agro-Chemical major.

This contract entrusts Vivo Bio Tech Limited with the end-to-end responsibility of conducting the full spectrum of pre-clinical safety and regulatory studies, including:

- Toxicity studies across multiple endpoints
- Mutagenicity evaluations to assess genetic safety
- Ecotoxicology studies for environmental risk assessment
- Comprehensive analytical services

All studies will be executed under the Section 9(3) requirements with regulatory submissions to the Central Insecticides Board & Registration Committee (CIBRC)—India's apex body for approvals.

By undertaking this comprehensive mandate, Vivo Bio Tech Limited joins a select group of CROs in India with the infrastructure and scientific expertise to deliver integrated pre-clinical solutions that meet both national and international regulatory standards.

Mr. Chandrasekar Patnaik, Chief Business Officer, Vivo Bio Tech Limited, said:

"This milestone reaffirms Vivo Bio Tech's scientific and technical excellence and strengthens our positioning as a trusted research partner for the global life sciences industry. It represents a major step forward in our mission to deliver innovative, reliable, and sustainable research services."

This landmark contract further underscores Vivo Bio Tech Limited's growing leadership across pharmaceuticals, agrochemicals, biotechnology, and environmental sciences. It reflects the company's long-term vision of evolving from a drug discovery services provider into a strategic co-innovator with large pharma and biotech companies. By enabling safer and more effective products to reach global markets while paving the way for future collaborations in joint drug discovery and milestone-driven partnerships, Vivo Bio Tech Limited is positioning itself as the ultimate benchmark of a next-generation CRO.